| scholarly article | Q13442814 |
| P50 | author | Finn Sellebjerg | Q59546273 |
| Luisa M Villar | Q41423098 | ||
| P2093 | author name string | Diego Cadavid | |
| Richard Reynolds | |||
| Deborah Steiner | |||
| Daniel Mikol | |||
| P2860 | cites work | Cortical demyelination in PML and MS: Similarities and differences | Q81391959 |
| Natalizumab treatment in multiple sclerosis: marked decline of chemokines and cytokines in cerebrospinal fluid | Q82230939 | ||
| Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients | Q82276225 | ||
| An unusual cause of multiple cerebral hemorrhages: drotrecogin alpha (activated protein C) | Q84068675 | ||
| Responsiveness of the Expanded Disability Status Scale (EDSS) to disease progression and therapeutic intervention in progressive forms of multiple sclerosis | Q85026366 | ||
| Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis | Q85156335 | ||
| Defining the clinical course of multiple sclerosis: the 2013 revisions | Q22241654 | ||
| Multiple sclerosis: Geoepidemiology, genetics and the environment | Q22252524 | ||
| B cell-attracting chemokine 1, a human CXC chemokine expressed in lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5 | Q24309316 | ||
| The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease | Q28207482 | ||
| A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1 | Q28263524 | ||
| Multiple sclerosis | Q28299151 | ||
| Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis | Q28535303 | ||
| Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis | Q28730755 | ||
| Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination | Q29614990 | ||
| A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis | Q29616119 | ||
| alpha4 Integrin/FN-CS1 mediated leukocyte adhesion to brain microvascular endothelial cells under flow conditions | Q30488236 | ||
| Downregulation of macrophage inhibitory molecules in multiple sclerosis lesions | Q30834408 | ||
| Multiple sclerosis: is there neurodegeneration independent from inflammation? | Q31105929 | ||
| Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis | Q31108462 | ||
| The pathology of multiple sclerosis: a historical perspective | Q33699357 | ||
| Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis | Q34104397 | ||
| The neuropathological basis of clinical progression in multiple sclerosis | Q34188436 | ||
| Sodium accumulation is associated with disability and a progressive course in multiple sclerosis. | Q34353593 | ||
| Natalizumab in the treatment of multiple sclerosis | Q34409340 | ||
| Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. | Q34413750 | ||
| Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis | Q34544889 | ||
| MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. | Q34621839 | ||
| Multiple sclerosis: an immune or neurodegenerative disorder? | Q34786872 | ||
| Activated microglia mediate axoglial disruption that contributes to axonal injury in multiple sclerosis | Q35103843 | ||
| Early treatment with anti-VLA-4 mAb can prevent the infiltration and/or development of pathogenic CD11b+CD4+ T cells in the CNS during progressive EAE. | Q35181321 | ||
| Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives | Q35182733 | ||
| Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid have less global and regional brain atrophy. | Q35202138 | ||
| Inflammatory cortical demyelination in early multiple sclerosis | Q35764685 | ||
| Lymphoid chemokines CCL19 and CCL21 are expressed in the central nervous system during experimental autoimmune encephalomyelitis: implications for the maintenance of chronic neuroinflammation. | Q48390605 | ||
| Extensive extracellular matrix depositions in active multiple sclerosis lesions | Q48411670 | ||
| A controlled trial of natalizumab for relapsing multiple sclerosis | Q48414534 | ||
| Cerebrospinal fluid immunological biomarkers associated with axonal damage in multiple sclerosis | Q48482480 | ||
| Benefit of interferon beta-1a on MSFC progression in secondary progressive MS. | Q48489376 | ||
| Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis | Q48523985 | ||
| Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cells | Q48660181 | ||
| Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment | Q48701331 | ||
| Cortical demyelination and diffuse white matter injury in multiple sclerosis. | Q48726181 | ||
| Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis | Q48873793 | ||
| Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab | Q48882820 | ||
| Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis | Q48949792 | ||
| The discovery of oligoclonal bands: a 50-year anniversary | Q49047601 | ||
| Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development | Q49074970 | ||
| The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. | Q50766232 | ||
| Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity. | Q50962057 | ||
| Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. | Q51027456 | ||
| Measuring myelin repair and axonal loss with diffusion tensor imaging. | Q51647645 | ||
| The effects of natalizumab on inflammatory mediators in multiple sclerosis: prospects for treatment-sensitive biomarkers. | Q51818901 | ||
| High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis. | Q53639982 | ||
| Multiple sclerosis: BAFF and CXCL13 in cerebrospinal fluid | Q59543689 | ||
| Suppression of established experimental autoimmune encephalomyelitis and formation of meningeal lymphoid follicles by lymphotoxin β receptor-Ig fusion protein | Q60455093 | ||
| Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial | Q61642982 | ||
| Gray matter atrophy is related to long-term disability in multiple sclerosis | Q61861932 | ||
| The natural history of multiple sclerosis: update 1998 | Q77563037 | ||
| Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis | Q79215413 | ||
| Increased PK11195 PET binding in the cortex of patients with MS correlates with disability | Q36146941 | ||
| Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status | Q36722852 | ||
| New concepts on progressive multiple sclerosis | Q36815387 | ||
| MRI dynamics of brain and spinal cord in progressive multiple sclerosis | Q36885926 | ||
| A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis | Q37101287 | ||
| The effects of natalizumab on the innate and adaptive immune system in the central nervous system | Q37161748 | ||
| Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy | Q37180592 | ||
| The relation between inflammation and neurodegeneration in multiple sclerosis brains. | Q37181308 | ||
| Lymphoid chemokines in chronic neuroinflammation | Q37186200 | ||
| Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. | Q37213706 | ||
| Monoclonal antibodies: what are the pharmacokinetic and pharmacodynamic considerations for drug development? | Q37976121 | ||
| Multiple Sclerosis Outcome Assessments Consortium: Genesis and initial project plan | Q38140702 | ||
| Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis. | Q38196701 | ||
| Pathological mechanisms in progressive multiple sclerosis | Q38378846 | ||
| In Vivo Detection of Diffuse Inflammation in Secondary Progressive Multiple Sclerosis Using PET Imaging and the Radioligand ¹¹C-PK11195. | Q39213875 | ||
| Immunoglobulin-containing cells in multiple-sclerosis plaques | Q39450637 | ||
| Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course. | Q39808939 | ||
| In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106. | Q40275502 | ||
| Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. | Q40431316 | ||
| Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. | Q42181572 | ||
| Accumulation of clonally related B lymphocytes in the cerebrospinal fluid of multiple sclerosis patients | Q42619341 | ||
| Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS. | Q43227358 | ||
| Serum levels of CXCL13 are elevated in active multiple sclerosis | Q43266829 | ||
| CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis | Q43502571 | ||
| Immunological markers of optimal response to natalizumab in multiple sclerosis. | Q43731725 | ||
| Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. | Q44028578 | ||
| Natalizumab plus interferon beta-1a for relapsing multiple sclerosis | Q44825022 | ||
| Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: a longitudinal study. | Q44869530 | ||
| The improvement of cognitive functions is associated with a decrease of plasma Osteopontin levels in Natalizumab treated relapsing multiple sclerosis. | Q45204560 | ||
| Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy | Q45405778 | ||
| Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. | Q46007698 | ||
| Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. | Q46078718 | ||
| A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS. | Q46273482 | ||
| Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. | Q47357498 | ||
| Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration | Q47680006 | ||
| Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis | Q47767879 | ||
| Fibronectin aggregation in multiple sclerosis lesions impairs remyelination | Q48187024 | ||
| Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. | Q48200750 | ||
| A longitudinal study of MRI-detected atrophy in secondary progressive multiple sclerosis | Q48215611 | ||
| Autologous haematopoietic stem cell transplantation fails to stop demyelination and neurodegeneration in multiple sclerosis | Q48276129 | ||
| Enhanced axonal metabolism during early natalizumab treatment in relapsing-remitting multiple sclerosis. | Q48296003 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | multiple sclerosis | Q8277 |
| secondary progressive multiple sclerosis | Q18965511 | ||
| P304 | page(s) | 31-43 | |
| P577 | publication date | 2016-01-01 | |
| P1433 | published in | Therapeutic advances in neurological disorders | Q26842039 |
| P1476 | title | Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis | |
| P478 | volume | 9 |
| Q53824259 | Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. |
| Q38558344 | Natalizumab for Multiple Sclerosis: A Case in Point for the Impact of Translational Neuroimmunology |
| Q57790000 | Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches |
| Q31114633 | Use of natalizumab in multiple sclerosis: current perspectives |
Search more.